Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY

v3.21.1
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - USD ($)
Common Shares
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Convertible Preferred Stock [Member]
Total
Balance at Dec. 31, 2019   $ 188,320,000 $ (48,000) $ (187,678,000) $ 517,000 $ 594,000
Balance (in shares) at Dec. 31, 2019 1,245,238       250,000  
Issuance of common stock and warrants, net of offering costs   725,000 0 0 $ 0 725,000
Issuance of common stock and warrants, net of offering costs (in shares) 91,062          
Issuance of common stock in connection with notes payable   4,000 0 0 0 4,000
Issuance of common stock in connection with notes payable (in shares) 500          
Issuance of warrants in connection with convertible notes payable   630,000 0 0 0 630,000
Convertible preferred stock dividend   (20,000) 0 0 20,000 (20,000)
Stock-based compensation   75,000 0 0 0 75,000
Stock-based compensation (in shares) 2,000          
Restricted stock awards cancelled   0 0 0 0 0
Restricted stock awards cancelled (in shares) (550)          
Release of vested restricted common stock   0 0 0 0 0
Release of vested restricted common stock (in shares) 353          
Net loss   0 0 (2,680,000) 0 (2,680,000)
Balance at Mar. 31, 2020 $ 0 189,734,000 (48,000) (190,358,000) $ 537,000 (672,000)
Balance (in shares) at Mar. 31, 2020 1,338,603       250,000  
Balance at Dec. 31, 2019   188,320,000 (48,000) (187,678,000) $ 517,000 594,000
Balance (in shares) at Dec. 31, 2019 1,245,238       250,000  
Balance at Dec. 31, 2020 $ 1,000 207,698,000 0 (200,383,000) $ 597,000 7,316,000 [1]
Balance (in shares) at Dec. 31, 2020 8,402,250       250,000  
Issuance of common stock in connection with notes payable (in shares)         0  
Warrants issued in connection with warrant exercise $ 0 567,000 0 0 $ 0 567,000
Issuance of common stock upon warrant exercise $ 0 5,095,000 0 0 0 5,095,000
Issuance of common stock upon warrant exercise (in shares) 2,086,251          
Convertible preferred stock dividend $ 0 (20,000) 0 0 20,000 (20,000)
Stock-based compensation $ 0 254,000 0 0 $ 0 254,000
Stock-based compensation (in shares) 643,700       0  
Release of vested restricted common stock $ 0 0 0 0 $ 0 0
Release of vested restricted common stock (in shares) 352          
Net loss $ 0 0 0 (3,292,000) 0 (3,292,000)
Balance at Mar. 31, 2021 $ 1,000 $ 213,594,000 $ 0 $ (203,675,000) $ 617,000 $ 9,920,000
Balance (in shares) at Mar. 31, 2021 11,132,553       250,000  
[1] The condensed consolidated balance sheet as of December 31, 2020 was derived from the audited consolidated balance sheet as of that date.